STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3768 by analyst upside · 2026-06-27
PTGX
Protagonist Therapeutics, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
-2.6%
implied upside to consensus target
Current Price $121.88
Consensus Target $118.69
Bull Target $137.0
Bear Target $100.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
9
Hold
1
Sell
0
52-Week Low $49.38
52-Week High $126.25
YTD Return +39.8%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E -178.0x
EPS (TTM) $-1.80
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $74M
Profit Margin -154.9%
52-WEEK RANGE
52-Week Low $49.38
52-Week High $126.25
Current Price $121.88
Bear Target $100.0
Bull Target $137.0
● Now $121.88 ● Target $118.69
TRADING DATA
Avg Volume 672K
YTD Return +39.8%
Analyst Count 13
Consensus Buy
Upside to Target -2.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Protagonist Therapeutics, Inc. (PTGX) is currently trading at $121.88 with a Wall Street consensus price target of $118.69, which is 2.6% below the current price over the next 12 months. 13 analysts currently cover PTGX, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $137.0, while the most cautious has a target of $100.0.

PTGX operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 39.8% year-to-date and is currently trading near the upper end of its 52-week range of $49.38 – $126.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PTGX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-06 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-05-06 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-04-15 Building track record
Clear Street — Reiterated
Buy → Buy 2026-04-07 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-03-19 29% win rate (7 calls)
JP Morgan — Reiterated
Overweight → Overweight 2026-03-19 43% win rate (7 calls)
Citigroup — Reiterated
Buy → Buy 2026-03-19 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-03-19 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
20/30
Consensus clarity
24/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →